Treatment-resistant Depression

Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant

Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression

First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression

Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression

First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression

Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression

Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment

UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center

Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation

Treatment-resistant Depression Recent News

Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression

COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary COM

GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading psychedelics stocks listed in Nasdaq, shared its financial results and business updates for its second quarter en

Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'

COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.)

COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital

Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist

Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD

Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for Treatment-Resistant Depression (TRD).

GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer

GH Research PLC (NASDAQ: GHRS), a Dublin-based clinical-stage biotech company reported financial results for the first quarter ended March 31, 2023.

Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression

Clinical-stage private biotech company Beckley Psytech Ltd announced that the first patient has been dosed in their Phase IIa study of BPL-003, a synthetic formulation of the psychedelic compound

Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results

After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche

Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far

Mental health care company COMPASS Pathways plc (NASDAQ: CMPS) has announced positive data demonstrating the potential of its proprietary synthetic psilocybin compound COMP360 in treating depression within Type II bipolar disorder.

Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments

(Part four of a four-part series) See previous stories:

Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes

(Part one of a four-part series)

Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders

Biotech company focused on creating next-gen serotonergic neuroplastogen psychedelic compounds to treat severe neuropsychiatric and neurological conditions Lusaris Therapeutics launched with a $60 million Series A financing.

atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing

Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for treatment-resistant depression (TRD).

Magic Mushrooms to Treat Anorexia? All About Compass' Novel Phase 2 Trial Of Psychedelic's Main Compound

Psychedelics mental healthcare company Compass Pathways PLC. (NASDAQ: CMPS) has launched a phase 2 clinical study testing the efficacy of psilocybin with psychological support in people with anorexia nervosa.

Magic Mushrooms Are More Effective Than Antidepressants In Treating Depression, New Study Shows

COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction

As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared to 1mg and 10mg) occasioned an increase in positive feelings of in

Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying

Besides being one of the most intimidating human beings ever to step into the boxing ring, former heavyweight champion Mike Tyson is also in the process of becoming a master at the art of dying.